Physician profile
Cynthia Gray
NPI 1104988336
$377.71
in general payments reported to CMS, 2019-2025
4 companies · $51.22 in 2025
The $51.22 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.66 · 2024: $240 · 2025: $51.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274 · Travel and Lodging: $16.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.49 |
| Travel and Lodging | $16.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $168.15 | 2024 | Arista Ah Flexitip |
| Mayne Pharma Commercial LLC | $105.40 | 2024-2025 | |
| Galderma Laboratories, L.P. | $90.46 | 2019-2024 | |
| Allergan, INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.